https://orcid.org/0000-0001-9971-9485
References
- Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:722.
- Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(5):40.
- Evans SJW, Douglas I, Rawlins MD, et al. Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013;84(10):1156–1160.
- Squitieri F, Griguoli A, Capelli G, et al. Epidemiology of Huntington disease: first post-HTT gene analysis of prevalence in Italy. Clin Genet. 2016;89(3):367–370.
- Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord. 2014;29(1):105–114.
- Rawlins M. Huntington’s disease out of the closet? Lancet. 2010;376(9750):1372–1373.
- Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of Huntington’s disease. Neuroepidemiology. 2016;46(2):144–153.
- Wexler NS, Collett L, Wexler AR, et al. Incidence of adult Huntington’s disease in the UK: a UK-based primary care study and a systematic review. BMJ Open. 2016;6(2):e009070.
- Exuzides A, et al. Epidemiology of Huntington’s Disease (HD) in the US medicare population (670). Neurology. 2020;94(15 Supplement):670.
- Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–216.
- Keum JW, Shin A, Gillis T, et al. The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. Am J Hum Genet. 2016;98(2):287–298.
- Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16(10):837–847.
- Simpson SA, Rae D. A standard of care for Huntington’s disease: who, what and why. Neurodegener Dis Manag. 2012;2(1):1–5.
- Divino V, Dekoven M, Warner JH, et al. The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ. 2013;16(8):1043–1050.
- Jones C, Busse M, Quinn L, et al. The societal cost of Huntington’s disease: are we underestimating the burden? Eur J Neurol. 2016;23(10):1588–1590.
- Murman DL, Chen Q, Colucci PM, et al. Comparison of healthcare utilization and direct costs in three degenerative dementias. Am J Geriatr Psychiatry. 2002;10(3):328–336.
- McCabe MP, O’Connor EJ. A longitudinal study of economic pressure among people living with a progressive neurological illness. Chronic Illn. 2009;5(3):177–183.
- Dubinsky RM. No going home for hospitalized Huntington’s disease patients. Mov Disord. 2005;20(10):1316–1322.
- Anderson KE, Divino V, DeKoven M, et al. Interventional differences among Huntington’s disease patients by disease progression in commercial and medicaid populations. J Huntingtons Dis. 2014;3(4):355–363.
- IBM MarketScan Research Databases White Paper for Life Sciences Researchers. 2020. [cited 2021 May 07]. Available from: https://www.ibm.com/products/marketscan-research-databases/resources.
- Measuring Price Change in the CPI: Medical care. 2020. [cited cited 2021 May 07]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm.
- Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. JMCP. 2010;16(9):703–712.
- Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson’s disease. Mov Disord. 2005;20(11):1449–1454.
- Joyce AT, Zhao Y, Bowman L, et al. Burden of illness among commercially insured patients with Alzheimer’s disease. Alzheimer’s Dementia. 2007;3(3):204–210.
- Consumer Price Index Inflation Calculator. 2022. [cited 2022 Feb 15]. Available from: https://data.bls.gov/cgi-bin/cpicalc.pl
- Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979;29(1):1–3.
- Winter Y, Balzer-Geldsetzer M, von Campenhausen S, et al. Trends in resource utilization for Parkinson’s disease in Germany. J Neurol Sci. 2010;294(1-2):18–22.
- Barer Y, Gavrielov N, Coloma P, et al. Huntington’s disease in Israel – 20 years of follow up from Maccabi healthcare services. Mov Disord. 2020;35(suppl 1). [cited 2022 May 23]. Available from: https://www.mdsabstracts.org/abstract/huntingtons-disease-in-israel-20-years-of-follow-up-from-maccabi-healthcare-services/
- Exuzides A, To TM, Abbass I, et al. Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population. Mov Disord. 2020;35(suppl 1). [cited 2022 May 23]. Available from: https://www.mdsabstracts.org/abstract/healthcare-resource-utilisation-and-costs-among-patients-with-versus-without-huntingtons-disease-in-the-us-population/